Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
Site for CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)(20-095)
Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
Locally-advanced or metastatic solid tumor with an NRG1 gene fusion Availability of fresh or archived tumor sample Minimum of one prior standard therapy appropriate for their tumor type and stage of disease, progressed or been nonresponsive to these available therapies ECOG performance status 0, 1 or 2 At least one measurable extra-cranial lesion
Exclusion Criteria:
Non •NRG-1 mutations Life expectancy < 3 months Pregnant or lactating Symptomatic or untreated brain metastases Known hypersensitivity to any of the components of seribantumab